logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharmaceuticals makes 'groundbreaking discovery' in its MATINS trial

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen speaks to Proactive London's Andrew Scott after updating on its phase I/II MATINS trial of Clevegen.

He says it's been encouraging to discover that Clevegen can ‘down’ regulate a range of checkpoints that affect the immune system.

Quick facts: Faron Pharmaceuticals Ltd

Price: 247.5 GBX

AIM:FARN
Market: AIM
Market Cap: £107.14 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Edenville Energy announces two big new offtake deals for...

Headlines from the Proactive UK newsroom. Edenville Energy’s (LON:EDL) signed two new significant contracts to supply washed coal from flagship Rukwa Coal Project in Tanzania. The new deals represent a supply of up to 9,000 tonnes per month, which is roughly 75% of the current capacity of the...

on 11/12/19

2 min read